Search

Gadopiclenol

Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA.

Ditiocarb zinc

Ditiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen. Sensitivity to ditiocarb zinc may be identified with a clinical patch test.

Vusolimogene oderparepvec

on anti-PD-1 therapy. … on a PD-1-blocking antibody-based regimen.

Ponesimod

Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]

Rocuronium

It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery … The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma.

Phenyl trimethicone

Dichromate

Rifamycin

The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. … [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]

Pegzilarginase

FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

Ospemifene

FDA approved on February 26, 2013.